Henry Schein, Inc. $HSIC Shares Purchased by Quantinno Capital Management LP

Quantinno Capital Management LP boosted its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 15.7% during the 1st quarter, Holdings Channel.com reports. The firm owned 108,653 shares of the company’s stock after acquiring an additional 14,756 shares during the period. Quantinno Capital Management LP’s holdings in Henry Schein were worth $8,008,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in HSIC. CYBER HORNET ETFs LLC purchased a new stake in Henry Schein during the second quarter worth approximately $25,000. MUFG Securities EMEA plc acquired a new stake in Henry Schein during the second quarter worth approximately $27,000. Flagship Harbor Advisors LLC acquired a new stake in Henry Schein during the fourth quarter worth approximately $30,000. Federated Hermes Inc. purchased a new stake in shares of Henry Schein during the 4th quarter worth approximately $32,000. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of Henry Schein during the 4th quarter worth approximately $37,000. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Analyst Ratings Changes

HSIC has been the topic of a number of research reports. Piper Sandler raised their price target on Henry Schein from $91.00 to $95.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. UBS Group reaffirmed a “neutral” rating and issued a $89.00 target price (up from $85.00) on shares of Henry Schein in a report on Tuesday, July 28th. BMO Capital Markets began coverage on shares of Henry Schein in a research report on Wednesday, July 8th. They set a “market perform” rating and a $85.00 price objective on the stock. BTIG Research upgraded shares of Henry Schein from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a research note on Thursday, June 11th. Finally, Robert W. Baird set a $97.00 target price on shares of Henry Schein in a research note on Wednesday, May 6th. Eight investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $89.36.

Trending Headlines about Henry Schein

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Quarterly results exceeded expectations. Henry Schein reported adjusted earnings of $1.27 per share, above the $1.22–$1.24 analyst consensus, while revenue reached $3.458 billion, topping estimates near $3.37 billion. Earnings increased from $1.10 per share in the year-ago quarter, and sales rose 6.7% year over year. Henry Schein Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Management raised its 2026 guidance. Henry Schein now expects adjusted diluted EPS of $5.29 to $5.39, sales growth of 4.5% to 5.5%, and adjusted EBITDA growth in the mid- to high-single digits. The $13.8 billion–$13.9 billion revenue outlook is above the roughly $13.7 billion analyst forecast, supporting the view that demand and profitability are improving. Henry Schein Reports Strong Second Quarter 2026 Financial Results and Raises FY2026 Guidance
• Positive Sentiment: Growth was broad-based. Global Distribution and Value-Added Services sales increased 6.6%, Specialty Products rose 8.7%, and Technology sales grew 8.2%. The company also repurchased approximately 2.6 million shares for $200 million during the quarter, providing additional support for per-share results. Henry Schein Q2 Revenue Rises 6.7 Percent
• Neutral Sentiment: The earnings call highlighted sustained sales momentum, margin improvement and solid operational execution. Investors will likely focus on whether stronger internal sales growth and the raised outlook can continue through the remainder of 2026. Henry Schein Q2 2026 Earnings Call Transcript
• Negative Sentiment: Recent insider activity was entirely selling, with executives reporting six sales and no purchases over the past six months. While these transactions may reflect personal liquidity decisions rather than business concerns, they are a modest cautionary signal for investors. Henry Schein Insider Trading Activity

Henry Schein Stock Up 3.0%

HSIC stock opened at $89.11 on Wednesday. The company has a 50 day moving average price of $82.74 and a two-hundred day moving average price of $78.47. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.75 and a current ratio of 1.36. The stock has a market capitalization of $10.15 billion, a P/E ratio of 26.92, a PEG ratio of 1.66 and a beta of 0.80. Henry Schein, Inc. has a one year low of $61.94 and a one year high of $92.18.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.24 by $0.03. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The business had revenue of $3.46 billion for the quarter, compared to analysts’ expectations of $3.37 billion. During the same period last year, the company earned $1.10 earnings per share. The company’s quarterly revenue was up 6.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. As a group, sell-side analysts expect that Henry Schein, Inc. will post 5.32 EPS for the current year.

Insider Activity at Henry Schein

In other news, Director William K. Daniel acquired 10,000 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were bought at an average price of $69.19 per share, for a total transaction of $691,900.00. Following the completion of the purchase, the director directly owned 20,000 shares of the company’s stock, valued at approximately $1,383,800. This trade represents a 100.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.89% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.